David Lebowitz
Stock Analyst at Citigroup
(2.44)
# 2,202
Out of 4,814 analysts
108
Total ratings
45.45%
Success rate
-1.98%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PLRX Pliant Therapeutics | Maintains: Neutral | $4 → $1.5 | $1.46 | +2.74% | 6 | Mar 4, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $12 → $14 | $7.27 | +92.70% | 7 | Feb 28, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $45 → $49 | $34.24 | +43.11% | 3 | Feb 21, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $67 → $64 | $28.32 | +125.99% | 12 | Feb 20, 2025 | |
| EXEL Exelixis | Maintains: Buy | $38 → $45 | $36.06 | +24.79% | 2 | Feb 12, 2025 | |
| PTCT PTC Therapeutics | Maintains: Sell | $32 → $45 | $47.45 | -5.16% | 4 | Feb 12, 2025 | |
| INCY Incyte | Maintains: Buy | $97 → $88 | $58.22 | +51.15% | 5 | Feb 11, 2025 | |
| VKTX Viking Therapeutics | Initiates: Neutral | $38 | $23.83 | +59.46% | 1 | Feb 7, 2025 | |
| CYTK Cytokinetics | Initiates: Buy | $86 | $39.48 | +117.83% | 1 | Feb 7, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $65 → $68 | $38.63 | +76.03% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $18.29 | +282.72% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $4.34 | +245.62% | 3 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $207 | $160.53 | +28.95% | 12 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $65 → $76 | $84.69 | -10.26% | 5 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $37 | $25.21 | +46.77% | 9 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $301.73 | +26.60% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $59.12 | +62.38% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $1.25 | +860.00% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $234.75 | -30.14% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $13.01 | +199.77% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $11.51 | +82.45% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $5.06 | +7,911.87% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $0.73 | +1,825.72% | 2 | Oct 12, 2021 |
Pliant Therapeutics
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.46
Upside: +2.74%
Intellia Therapeutics
Feb 28, 2025
Maintains: Neutral
Price Target: $12 → $14
Current: $7.27
Upside: +92.70%
BridgeBio Pharma
Feb 21, 2025
Maintains: Buy
Price Target: $45 → $49
Current: $34.24
Upside: +43.11%
Ionis Pharmaceuticals
Feb 20, 2025
Maintains: Buy
Price Target: $67 → $64
Current: $28.32
Upside: +125.99%
Exelixis
Feb 12, 2025
Maintains: Buy
Price Target: $38 → $45
Current: $36.06
Upside: +24.79%
PTC Therapeutics
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $47.45
Upside: -5.16%
Incyte
Feb 11, 2025
Maintains: Buy
Price Target: $97 → $88
Current: $58.22
Upside: +51.15%
Viking Therapeutics
Feb 7, 2025
Initiates: Neutral
Price Target: $38
Current: $23.83
Upside: +59.46%
Cytokinetics
Feb 7, 2025
Initiates: Buy
Price Target: $86
Current: $39.48
Upside: +117.83%
Mirum Pharmaceuticals
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $38.63
Upside: +76.03%
Oct 7, 2024
Initiates: Buy
Price Target: $70
Current: $18.29
Upside: +282.72%
Sep 24, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $4.34
Upside: +245.62%
Sep 17, 2024
Maintains: Buy
Price Target: $178 → $207
Current: $160.53
Upside: +28.95%
May 3, 2024
Maintains: Sell
Price Target: $65 → $76
Current: $84.69
Upside: -10.26%
May 2, 2024
Maintains: Buy
Price Target: $39 → $37
Current: $25.21
Upside: +46.77%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $301.73
Upside: +26.60%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $59.12
Upside: +62.38%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $1.25
Upside: +860.00%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $234.75
Upside: -30.14%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $13.01
Upside: +199.77%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $11.51
Upside: +82.45%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $5.06
Upside: +7,911.87%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $0.73
Upside: +1,825.72%